CareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business O...
November 26 2018 - 4:01PM
CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics
company focused on the discovery, development and commercialization
of clinically differentiated, high-value diagnostic solutions for
transplant patients, today announced that Reginald Seeto,
MB.BS., has joined the company in the newly created role of
President and Chief Business Officer. His
appointment was effective Monday, November 26, 2018.
Dr. Seeto brings 20 years of experience in commercial
operations, corporate development and strategy, and executive
leadership to CareDx. Before joining CareDx, Dr. Seeto was Chief
Operating Officer at Ardelyx leading pre-launch efforts for
tenapanor and corporate development, where he completed a
series of partnerships. Prior to this, Dr. Seeto worked at
AstraZeneca/Medimmune and was a member of the MedImmune Executive
Team. His responsibilities over 8 years included leading corporate
development and strategy, global strategic marketing and portfolio
management for all therapeutic areas, as well as a country
leadership role at AstraZeneca in Thailand.
Earlier in his career, Dr. Seeto held positions of
increasing responsibility at Organon Biosciences, where he led the
marketing and medical teams for the Fertility, Immunology, Oncology
and Vaccine Franchises, and was the US Brand Team Leader for
Flomax at Boehringer Ingelheim. He started his
career as a physician, during which time he performed a medical
rotation in a renal transplant unit, before joining McKinsey and
Company.
"We are thrilled to have such a talented individual join CareDx.
Reg’s breadth of experience and performance track-record represent
the ideal combination as we enter a new phase of accelerated
growth. Reg will primarily focus on strengthening and developing
our business operations, as we continue to build a
powerhouse in personalized medicine. His experience with
transformational growth will be especially valuable as we scale the
organization and further expand geographically,” said Peter
Maag, CEO of CareDx.
About CareDx CareDx,
Inc., headquartered in Brisbane, California, is a molecular
diagnostics company focused on the discovery, development and
commercialization of clinically differentiated, high-value
diagnostic solutions for transplant recipients. CareDx offers
products along the pre- and post-transplant testing continuum.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements,
including expectations regarding the Company’s business operations,
plans and potential growth. These forward-looking statements are
based upon information that is currently available to CareDx and
its current expectations, speak only as of the date hereof, and are
subject to numerous risks and uncertainties, including general
economic and market factors, among others discussed in CareDx’s
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2017 filed by CareDx with the
SEC on March 22, 2018 and the periodic reports that CareDx has
subsequently filed with the SEC. Any of these may cause CareDx’s
actual results, performance or achievements to differ materially
and adversely from those anticipated or implied by CareDx’s
forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
CONTACTS:
Investor RelationsDavid ClairIntegrated Corporate Relations,
Inc.646-277-1266david.clair@icrinc.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024